Trial · NCT02556346
Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT02556346, Phase 1, Withdrawn, Molecular Templates, Inc.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma. Trials, record NCT02556346. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02556346
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- NCT number
- NCT02556346
- Status
- Withdrawn
- Phases
- Phase 1
- Enrollment
- 0 participants, actual
- Lead sponsor
- Molecular Templates, Inc.
- Conditions
- Chronic B-cell Lymphocytic Leukemia, Small Lymphocytic Leukemia
- Interventions
- MT-3724, MT-3724, MT-3724, MT-3724, MT-3724
- First posted
- 2015-09-22
- Last updated
- 2016-03-02
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Tolerability as measured by number of subjects with dose limiting toxicities | 28 days | Evaluation of tolerability of MT-3724 measured by number of subjects with dose limiting toxicities (DLTs) |
| Primary | Safety as measured by number of subjects with Adverse Events using CTCAE | 28 days and then every 6 months for up to 24 months following first dose if subject does not continue into Phase Ib | Safety measured by number of subjects with Adverse Events using CTCAE Version 4.03 |
| Primary | Tolerability as measured by adverse events using CTCAE and clinical laboratory parameters | 2-3 weeks following last dose and then every 6 months for up to 24 months following first dose | Evaluation of tolerability of MT-3724 given for up to 4 additional cycles measured by number, nature and severity of Adverse Events using CTCAE Version 4.03 |
| Secondary | PK as measured by concentrations of free MT-3724 (Cmax, Cinf) | Days 1, 5, 8, 12, 23, and 28 | Evaluation of the pharmacokinetic profile of MT-3724 |
| Secondary | PK as measured by area under the curve of free MT-3724 (AUC) | Days 1, 5, 8, 12, 23, and 28 | Evaluation of the pharmacokinetic profile of MT-3724 |
| Secondary | PK as measured by time to maximum concentration of free MT-3724 ( tmax) | Days 1, 5, 8, 12, 23, and 28 | Evaluation of the pharmacokinetic profile of MT-3724 |
| Secondary | PD as measured by immunogenicity (anti-drug antibodies) | During Screening, Days 23-25, Day 1 of cycle 2, and at final end of study visit | Evaluation of the pharmacodynamic profile of MT-3724 |
| Secondary | Tumor Response as measured by PET or CT scan | During Screening, Days 43 & 86 | Evaluation of tumor response using International Working Group Response Criteria |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02556346
GET https://conductscience.org/api/trials/v1/NCT02556346/registered